Results of FDA review of mifepristone
Today, we have learned that the US Food and Drug Administration’s review of the risk evaluation and mitigation strategy (REMS) for mifepristone has resulted in removing some outdated barriers. Notably, pharmacy access, previously limited by the FDA and allowed during the pandemic, will be made permanent. This change aligns with the evidence and the Society of Family Planning celebrates the centering of the science around this aspect of the REMS. That said, the FDA unfortunately still retained some medically unnecessary restrictions on this safe and effective medication. The Society and its members will continue the work to capture and uplift the scientific evidence around mifepristone's safety and efficacy with an eye towards removing unnecessary barriers that impede people’s access to this important medication.